
A transgender woman incarcerated in a federal prison sits alone in her cell, reflecting the growing controversy over policies that could force transgender inmates off hormone therapy under Executive Order 14168. (Image generated by ChatGPT using DALL·E, 2026.)
Executive Order 14168, issued on January 20, 2025 and titled Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, has reshaped how transgender people are treated by federal institutions. While much public discussion has centered on gender markers or legal recognition of transgender identity, one of the most immediate and dangerous consequences of the order has emerged inside the federal prison system. In particular, policy changes following the order have led to attempts by federal prison authorities to discontinue hormone therapy and other gender-affirming medical treatments for incarcerated transgender people. For many transgender inmates, this policy shift represents not only a denial of identity but also a serious threat to physical and psychological health. At the same time, the logic behind these policies raises broader concerns about how transgender people may be treated by federal institutions beyond the prison system.
The executive order directs federal agencies to recognize only two sexes—male and female—defined as immutable and determined at conception (The White House, 2025). This directive eliminates gender identity as a category recognized in federal administration. When applied to the federal prison system, the policy affects how prisoners are classified, housed, and treated medically. Most critically, it has been used to justify attempts to eliminate or restrict gender-affirming healthcare for incarcerated transgender people.
Gender-affirming hormone therapy is widely recognized by major medical organizations as a necessary treatment for individuals diagnosed with gender dysphoria. Medical consensus holds that hormone therapy can significantly reduce psychological distress, depression, and suicide risk among transgender patients. Within prison environments—where individuals already face isolation, stress, and restricted autonomy—continuity of medical care is considered especially important. Nevertheless, following the issuance of Executive Order 14168, federal prison officials moved to halt or restrict such treatment.
Reporting by the Associated Press indicates that the policy shift prompted the Federal Bureau of Prisons to attempt to terminate or suspend hormone therapy for transgender inmates in federal custody (Riccardi & Kunzelman, 2025). The decision sparked immediate legal challenges from incarcerated transgender individuals who argued that the abrupt withdrawal of medically prescribed treatment would cause severe harm. In multiple cases, courts were asked to intervene to prevent the termination of hormone therapy.
In June 2025, a federal judge ruled that the Bureau of Prisons must continue providing hormone therapy to transgender inmates while litigation proceeds. Reuters journalist Nate Raymond reported that the court found the government had failed to justify abruptly ending treatment that physicians had previously deemed medically necessary (Raymond, 2025). The ruling emphasized that forcing transgender prisoners to discontinue hormone therapy could produce serious psychological consequences and potentially violate constitutional protections against cruel and unusual punishment.
Despite these court rulings, recent reporting suggests that federal prison policies continue to move toward restricting gender-affirming care. In March 2026, Samantha Riedel reported in Them that federal prison authorities had begun implementing policies requiring transgender inmates receiving hormone therapy to gradually discontinue those medications (Riedel, 2026). According to medical experts cited in the report, forced withdrawal from hormone therapy can lead to severe depression, anxiety, and increased risk of self-harm. For individuals who have relied on hormone therapy for years as part of a medically supervised transition, being forced off treatment can trigger profound physical and psychological distress.
These medical risks are particularly concerning in correctional environments. Prison systems already struggle with high rates of mental health crises, and incarcerated individuals frequently have limited access to specialized medical care. When transgender inmates are forced off hormone therapy, the resulting psychological distress can be intensified by the conditions of confinement, including isolation, stigma, and lack of support networks. The loss of hormone therapy can also have visible physical effects that may expose transgender prisoners to additional harassment or violence from other inmates.
Although these developments are occurring within federal prisons, the implications extend beyond incarcerated populations. Policies implemented within prisons often reflect broader ideological frameworks that can shape how government agencies treat marginalized groups more generally. When federal policy defines sex as immutable and rejects the legitimacy of gender identity, that definition may influence how transgender people are treated across a wide range of institutions, including healthcare systems, identification programs, and federal employment policies.
The attempt to eliminate hormone therapy for transgender prisoners demonstrates how quickly policy can shift from symbolic definitions to control over medical care and bodily autonomy. If federal institutions can deny gender-affirming treatment to incarcerated individuals based on a policy redefining sex, similar arguments could potentially be used to justify restrictions in other contexts. While prisoners occupy a uniquely vulnerable position under government authority, policies affecting them can serve as testing grounds for broader administrative approaches.
History offers numerous examples in which policies applied first to prisoners or other marginalized groups later expand into wider legal frameworks. In the case of Executive Order 14168, the removal of gender identity from federal policy raises concerns that transgender people may face increasing barriers to medical care and legal recognition across multiple institutions. For transgender Americans, the developments within federal prisons therefore represent more than a correctional policy dispute; they signal how federal authority may increasingly regulate transgender bodies and identities.
The ongoing legal challenges surrounding hormone therapy in federal prisons will play a significant role in determining the future of transgender healthcare within federal institutions. Courts must decide whether the abrupt withdrawal of medically necessary treatment constitutes deliberate indifference to serious medical needs, which could violate the Eighth Amendment’s prohibition on cruel and unusual punishment. The outcome of these cases will shape not only the lives of transgender prisoners but also the broader legal landscape governing transgender rights in the United States.
Executive Order 14168 has therefore created a situation in which the treatment of transgender inmates has become a focal point in a larger struggle over recognition, medical care, and bodily autonomy. The attempt to force transgender prisoners off hormone therapy illustrates how administrative policy decisions can translate into immediate and profound consequences for vulnerable individuals. At the same time, it raises deeper questions about how far such policies might extend and what they could mean for transgender people beyond prison walls.
References
Raymond, N. (2025, June 3). U.S. judge says federal prisons must continue hormone therapy for transgender inmates. Reuters. https://www.reuters.com/legal/us-judge-orders-prisons-continue-hormone-therapy-transgender-inmates
Riccardi, N., & Kunzelman, M. (2025, January 23). What to know about President Donald Trump’s order targeting transgender rights. Associated Press. https://apnews.com/article/trump-transgender-passports-prisons-eggs-sperm-da1d1d280658a8c85c57cfec2f30cefb
Riedel, S. (2026, March 10). Federal prisons are beginning to force trans inmates off hormone therapy. Them. https://www.them.us/story/federal-prisons-are-beginning-to-force-trans-inmates-off-hormone-therapy
The White House. (2025). Executive Order 14168: Defending women from gender ideology extremism and restoring biological truth to the federal government. https://public-inspection.federalregister.gov/2025-02090.pdf

In recent years, a troubling trend has emerged across the United States: the introduction and enactment of laws that effectively criminalize aspects of being transgender. These laws go beyond limiting access to medical care or restricting participation in public life; they represent a broader effort to marginalize and erase transgender individuals.
OPM Ends Gender-Affirming Care in 2026
By Katherine Walter
On August 25, 2025
In LGBTQ+ rights
To understand the gravity of this reversal, it is necessary to recall how hard-fought the gains for transgender health care under FEHB were. In 2014, OPM lifted the longstanding blanket exclusion of gender-affirming procedures, and by 2016 carriers were instructed not to categorically deny such care. This change aligned federal benefits with emerging medical consensus that gender-affirming treatments are not elective but medically necessary. The World Professional Association for Transgender Health (WPATH) and the Endocrine Society have long affirmed that access to hormone therapy and surgeries significantly reduces psychological distress, improves quality of life, and prevents serious health complications (Hembree et al., 2017; Coleman et al., 2022). For nearly a decade, transgender federal employees and retirees could rely on this coverage as a matter of equity and recognition of their humanity.
As a transgender woman who has been receiving gender-affirming health care for more than eleven years, this policy shift strikes me not just as a bureaucratic adjustment but as a direct threat to my life and well-being. Having undergone an orchiectomy, I rely on estradiol not simply as an affirming treatment, but as essential hormone replacement. Without it, my bones, cardiovascular health, cognition, and emotional stability would be at severe risk. Estradiol for me is no different than thyroid medication for someone with hypothyroidism—it is medically necessary, lifelong care. To see it lumped under a politically charged category of “optional” transition services is both scientifically inaccurate and deeply insulting.
What unsettles me most is the uncertainty this policy creates. OPM’s promise of an “exceptions process” offers little clarity. Will it protect those of us with medical histories spanning over a decade of consistent care? Or will it force us into endless appeals and denials, treating every prescription refill as a battle? This ambiguity is destabilizing, and I cannot help but feel that it is intentional—designed to make care harder to access and to discourage providers from stepping forward.
As a federal retiree, I gave years of service under the assumption that the benefits I earned would protect me equitably. Now, I feel as though my identity has made me a target within the very system I trusted. The estimated 14,000 transgender federal employees and retirees who will be affected are not faceless statistics; we are people who dedicated our careers to serving this country, only to be told that our health care needs are unworthy of recognition (Lambda Legal, 2025; them.us, 2025). The exclusion also signals a dangerous precedent: that essential medical care can be stripped away not because of evidence or cost, but because of politics.
This change must be understood in its broader social context. Over the past decade, transgender Americans have seen both progress and backlash. The Affordable Care Act’s Section 1557 extended nondiscrimination protections in health care, and the Supreme Court’s ruling in Bostock v. Clayton County (2020) affirmed that gender identity is protected under Title VII. Yet, simultaneously, states across the country have passed laws restricting access to gender-affirming care, particularly for youth, framing these measures as cultural wedge issues. The OPM directive extends that wave of exclusion into the federal system, embedding discrimination into the nation’s largest employer-based insurance program.
For me personally, this is not an abstract policy debate. It is about whether I will be able to continue accessing the medication that keeps me healthy and alive. It is about whether the years of progress we celebrated were only temporary reprieves. And it is about what message this sends to younger transgender people entering federal service today: that their health and dignity can be used as bargaining chips in political battles.
I cannot help but feel anxious about what the future holds, but I also feel resolved. This rollback will not go unchallenged. Advocacy groups such as Lambda Legal, the National Center for Transgender Equality, and others have already condemned it as unlawful and are preparing legal strategies (Lambda Legal, 2025). As a transgender woman and a retiree, I plan to add my voice to that chorus, because silence is what allows discrimination to endure. We have fought too hard, and for too long, to let the ground be taken out from under us without resistance.
References
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., … Winter, S. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health, 23(sup1), S1–S259. https://doi.org/10.1080/26895269.2022.2100644
Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., … T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658
Lambda Legal. (2025, August 19). Lambda Legal condemns Trump administration’s illegal exclusion of gender-affirming care from employee health benefits. Retrieved August 22, 2025, from https://lambdalegal.org/newsroom
Moss, K. (2025, August 20). Coverage for gender-affirming care will be eliminated from FEHB plans in 2026. Government Executive. Retrieved August 22, 2025, from https://www.govexec.com
Office of Personnel Management. (2025). Carrier Letter 2025-01b: Chemical and surgical sex-trait modification exclusion. Retrieved August 22, 2025, from https://opm.gov
them.us. (2025, August 20). Trump Admin to end coverage of gender-affirming care for federal workers. them. Retrieved August 22, 2025, from https://www.them